Non-Alcoholic Fatty Liver Disease
Conditions
Brief summary
Nonalcoholic steatohepatitis (NASH) is now recognised as an increasing clinical problem in children. Steatosis without significant liver cell injury or fibrosis is the most common form of nonalcoholic fatty liver disease (NAFLD) in both adults and children. Studies in the adult population have variably suggested that steatosis is a benign nonprogressive condition and NASH is recognised as a potentially serious condition with significantly risk of morbidity and mortality. A growing body of evidence suggests that children with NASH frequently show histopathological features that differ from those of adults. The prevalence of this pattern in a wide range of paediatric cases as well as other histopathological lesions and their relevance and prognostic significance in children with NAFLD remains to be determined. Thus the investigators would like to conduct a study of biopsies and clinical information to document the histological features of paediatric NAFLD, to explore the natural history of paediatric NAFLD, and to determine the frequency and prognostic value of these features.
Interventions
OTHERNo intervention
There will be no specific intervention to these paediatric NASH patient
Sponsors
Humanity and Health Research Centre
Beijing 302 Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Inclusion criteria
* age 1-18 with biopsy-proven NAFLD * Alcohol consumption less than 20g/day and 10g/day for boys and girls respectively
Exclusion criteria
* with viral hepatitis, e.g. HBV, HCV * with a1-anti-trypsin disease * with autoimmune hepatitis * with Wilson disease * with liver impaired by drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Liver related death | Through study completion, an average of 1 year | Whether the patients die from liver-related causes |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complications of cirrhosis | Through study completion, an average of 1 year | Whether the complication of cirrhosis i.e. ascites, hepatic encephalopathy, variceal bleeding occur during the follow-up |
| Liver biopsy | Through study completion, an average of 2 year | — |
| Liver transplant | Through study completion, an average of 1 year | Whether the patients have liver transplant during the follow-up |
Countries
China
Contacts
CONTACTGeorge Lau, MD, PhD
CONTACTYudong Wang, MD, PhD
PRINCIPAL_INVESTIGATORGeorge Lau, MD, PhD
Humanity and Health Medical Centre
Outcome results
None listed